EU Regulatory Assessment

How MedRegChat Works

MedRegChat runs in two phases. Phase 1 is a structured Q&A that determines which EU regulations apply to your product. Phase 2 (optional) digs deeper into your intended use to generate a draft Instructions for Use (IFU) document — a legal requirement for CE marking under MDR.

Phase 1 — Regulatory Classification
Product Info Company, product name & description
MDR
IVDR
AI Act
GDPR
AI Summary & PDF Report Classification results + next steps
optional ↓
Phase 2 — Instructions for Use (IFU) Deep-Dive
5 Targeted Questions Indications · Users · Population · Setting · Contraindications
AI-Generated IFU Draft Instructions for Use — MDR Annex I, Section 23
Full PDF Report Classification + IFU draft sections
Phase 1 — Decision Paths
1

MDR Medical Device Regulation (EU) 2017/745

Determines whether your product qualifies as a medical device and assigns a risk class. Applies to any device with a medical purpose, from bandages to implants to diagnostic software.

Decision path

  • Is it a medical device? — Does it have a medical purpose: diagnosis, treatment, monitoring, or prevention of disease or injury?
  • SaMD or physical device? — Software as a Medical Device (SaMD) that runs on its own follows a sub-path based on clinical significance and the severity of the condition it addresses.
  • For physical devices — Is it invasive (enters the body surgically or through a natural opening) or non-invasive? Duration of use also affects the class.
  • Classification result — Class I (lowest risk), IIa, IIb, or III (highest risk, requires Notified Body involvement for CE marking).
Class I Class IIa Class IIb Class III
2

IVDR In Vitro Diagnostic Regulation (EU) 2017/746

Assessed separately from MDR. Applies if your product tests specimens taken from the human body — blood, urine, saliva, tissue — to obtain diagnostic or monitoring information.

Decision path

  • Is it an IVD? — Does it analyse body specimens (in vitro = outside the body)?
  • IVD type — Self-testing (e.g. home pregnancy test), companion diagnostic (guides therapy choice), blood/organ screening, transmissible-agent detection, or general lab-based IVD.
  • Risk of incorrect result — What happens if the test gives a false positive or false negative? Low impact → Class A; life-threatening impact → Class D.
Class A Class B Class C Class D
3

AI Act EU Artificial Intelligence Act (2024/1689)

The world's first comprehensive AI law. Determines whether your product uses AI or machine learning (ML) and assigns a risk tier, which drives transparency and conformity obligations.

Decision path

  • Does it use AI/ML? — Machine learning, neural networks, or any system trained on data to make predictions. Simple rule-based logic (if/then) does not count.
  • Primary use case — Clinical diagnosis, medical image analysis, or patient triage → automatically High risk. Administrative/workflow use → depends on patient data contact.
  • Patient data contact — Administrative AI that interacts with patient data is Limited risk; administrative AI with no patient data is Minimal risk.
Minimal risk Limited risk High risk
4

GDPR General Data Protection Regulation (EU) 2016/679

Applies whenever your product processes personal data — any information that can identify a living person, directly or indirectly. Health and biometric data are "special category" data with stricter rules.

Decision path

  • Personal data? — Names, health records, diagnoses, biometric data (fingerprints, face scans), IP addresses, or device identifiers linked to a person.
  • Your organisation's role — Do you decide why and how data is processed (Data Controller), or do you process data on instructions from another organisation (Data Processor), or both jointly (Joint Controller)?
Controller Processor Joint Controller
Phase 2 — Instructions for Use (IFU) Deep-Dive

IFU Deep-Dive Instructions for Use — MDR Annex I, Section 23

An optional second phase that collects the details needed to draft your Instructions for Use (IFU) — the document that must accompany every CE-marked medical device. The IFU describes the intended purpose and safe-use conditions. It is also the foundation for your clinical evaluation and predicate identification under MDR.

5 questions — what each one feeds into

  • Specific indications — The exact medical conditions or clinical problems the device addresses. This becomes the "Indications for Use" section.
  • Intended users — Healthcare Professional, Patient/Caregiver, Trained Technician, or multiple. Determines the required training and labelling language.
  • Patient population — Demographics (age, sex), clinical criteria, and exclusion criteria. Required under MDR Article 10 and Annex I §23.4.
  • Clinical setting — Hospital/Clinic, Home Use, Operating Room, Point-of-Care, or multiple. Affects safety requirements and post-market surveillance.
  • Contraindications — Patient groups or situations where the device must NOT be used (e.g. pacemaker wearers, pregnant patients, latex allergy).
Intended Purpose Statement Indications for Use Contraindications Intended Users Clinical Setting Patient Population

Abbreviations & Key Terms

Term Full name & meaning
MDR Medical Device Regulation — EU Regulation 2017/745. The primary law governing medical devices placed on the EU market. Replaced the older MDD (Medical Device Directive) from 2021.
IVDR In Vitro Diagnostic Regulation — EU Regulation 2017/746. Governs diagnostic products that test specimens (blood, urine, tissue) taken outside the body. Replaced the old IVDD (IVD Directive) from 2022.
IVD In Vitro Diagnostic — Any reagent, instrument, or system used to examine a specimen derived from the human body for diagnostic or monitoring purposes. "In vitro" means "in glass" (outside the body).
SaMD Software as a Medical Device — Software that performs a medical function on its own, without being embedded in physical hardware. An AI diagnostic app is SaMD; firmware inside a blood pressure monitor is not.
AI Act EU Artificial Intelligence Act — Regulation (EU) 2024/1689. The world's first comprehensive AI law, using a risk-based approach: Minimal, Limited, High, and Unacceptable risk tiers.
ML Machine Learning — A type of AI where a system learns patterns from data rather than following explicit rules. Includes neural networks, deep learning, and classical ML models.
GDPR General Data Protection Regulation — EU Regulation 2016/679. Governs the collection, storage, and processing of personal data of EU residents. Health data is "special category" data requiring explicit consent and stricter safeguards.
IFU Instructions for Use — The document accompanying a medical device that describes its intended purpose, how to use it safely, indications, contraindications, and warnings. Mandated by MDR Annex I, Section 23.
CE marking Conformité Européenne — The mark showing a product meets EU safety, health, and environmental requirements. Required to legally sell medical devices in the EU/EEA.
Notified Body An independent organisation designated by EU member states to audit and certify that higher-risk devices (Class IIa, IIb, III under MDR; Class B, C, D under IVDR) meet regulatory requirements before CE marking.
EUDAMED European Database on Medical Devices — The EU's central database for registering devices, manufacturers, and clinical investigations under MDR/IVDR.
Clinical Evaluation The systematic process a manufacturer uses to demonstrate that a device is safe and performs as intended, based on clinical data. Required for all CE-marked medical devices under MDR Annex XIV.
Predicate Device An existing legally marketed device with a similar intended use, used as a reference point in a clinical evaluation to demonstrate equivalence.
MDD Medical Device Directive (93/42/EEC) — The predecessor to MDR, now replaced. Devices certified under MDD required re-certification under MDR by September 2025 at the latest.
DPIA Data Protection Impact Assessment — A GDPR requirement for processing activities that are likely to result in a high risk to individuals, such as large-scale health data processing. Data Controllers must conduct a DPIA before starting such processing.

Each phase is independent. Phase 1 evaluates all four regulatory frameworks — your product may fall under one, several, or all of them. Phase 2 is optional and focused solely on drafting IFU content. The final PDF report consolidates everything.

Disclaimer: MedRegChat provides educational guidance only and does not constitute legal or regulatory advice. Always consult a qualified Regulatory Affairs specialist or Notified Body before making compliance decisions.

Start Assessment